U.S. relatively hospitable to stem-cell research

The United States appears to be a relatively hospitable place for embryonic stem cell research, especially compared to Canada and some nations in Europe where governments not only refuse financial support for human cloning to produce stem cells, they outlaw the practice.


Drug firms don't disclose enough

The editor-in-chief of the New England Journal of Medicine accused three of the largest drug companies of ‘making a mockery‘ of efforts to create transparency in clinical trials, adding that could lead some important medical publications to avoid publishing their studies.


Drug firms don’t disclose enough

The editor-in-chief of the New England Journal of Medicine accused three of the largest drug companies of ‘making a mockery‘ of efforts to create transparency in clinical trials, adding that could lead some important medical publications to avoid publishing their studies.


Alternative Stem Cell Bill Added to Debate

With a closely divided House poised to vote today on whether to expand federal funding of human embryonic stem cell research, opponents are offering fence-sitters what they say is an embryo-friendly alternative: a bill that would foster the use of stem cells from umbilical cords discarded after birth.


Brand Drug Prices Outpace Inflation

U.S. prices for brand-name drugs on average rose at 2.5 times the rate of inflation last year, while generic drug prices remained flat, according to a study released on Tuesday by the nation’s largest lobby for the elderly.


Do NOT follow this link or you will be banned from the site!
Get email updates

Get new actionable insights and updates from BiotechBlog